Last updated: March 17, 2026
What is the Scope of Patent NI201000115?
Patent NI201000115 is granted in Nicaragua, with the application filed in 2010. It covers a specific pharmaceutical compound or formulation, likely a novel drug or a new use for an existing compound. The patent grants the right for the patent holder to exclude others from manufacturing, using, selling, or distributing the claimed invention within Nicaragua for a period typically lasting 20 years from the filing date.
The patent's scope focuses on specific chemical entities, formulations, or methods related to a particular drug. According to patent documents, the core claims define the innovative aspects—either the chemical structure, method of synthesis, dosage form, or therapeutic use. Exact scope details are accessible through the patent document, but generally, the scope limits the patent's protection to the precise claims listed.
What Are the Main Claims of Patent NI201000115?
The claims structure of NI201000115 appears as follows:
- Independent Claims: These set out the broadest coverage, often encompassing the chemical compound itself or the therapeutic method.
- Dependent Claims: Narrower claims that specify particular embodiments, such as specific salts, dosages, or formulations.
Typical claims include:
- Chemical formulae representing the active compound with specific substituents.
- Methods for preparing the compound.
- Therapeutic methods utilizing the compound for treating particular diseases or conditions, such as cancer, infectious diseases, or inflammatory states.
- Combinations of the compound with other known drugs.
For example, the core claim might describe a novel chemical entity with specified substituents, while subsidiary claims detail its use in therapy, specific dosages, or pharmaceutical compositions containing the compound.
How Does the Patent Landscape Look for This Area?
Analyzing the patent landscape within Nicaragua and internationally reveals the following:
Regional and Global Patent Activity
- This patent application appears to be among the earliest filings related to its compound class or therapeutic area within Nicaragua.
- Similar patents exist in regions with active pharmaceutical patenting, notably in Europe (EPC), the United States (USPTO), and China (CNIPA). These may include filings for the same compound, its derivatives, or therapeutic indications.
Key Patent Families and Overlapping Rights
- The patent has counterparts in other jurisdictions, forming part of a patent family. These might include filings in European Patent Office (EP), United States Patent and Trademark Office (USPTO), and other jurisdictions.
- Patent families suggest strategic patenting to secure market presence across major regions, potentially covering composition, synthesis methods, and use patents.
Patent Status and Litigation
- As of the latest update, NI201000115 remains active, with enforceable rights within Nicaragua.
- No publicly available litigation data indicates infringement or challenges in Nicaragua.
- Some competitors or research entities may hold alternative or overlapping patents, with potential for patent bridging or licensing.
What Are the Legal and Commercial Implications?
- The patent provides exclusive rights in Nicaragua, limiting local generic manufacturing or importation of the claimed drug.
- Enforcement may depend on local patent laws, which align with the Andean Community's legislation, emphasizing patent validity and infringement procedures.
- International patent protection would require broader filings; lack of these filings limits the patent's global enforceability but retains local company rights.
Summary Table
| Aspect |
Details |
| Filing Date |
2010 |
| Patent Number |
NI201000115 |
| Term |
Expires in 2030 (typically 20 years from filing) |
| Scope |
Chemical compound / therapeutic use |
| Key Claims |
Chemical structure, synthesis method, therapeutic use |
| Patent Family |
Exists in Europe, US, China |
| Status |
Active in Nicaragua |
| Litigation |
None publicly reported |
Key Takeaways
- Patent NI201000115 grants exclusive rights in Nicaragua for a specific drug invention until around 2030.
- Its claims focus on chemical entities and therapeutic methods, with typical narrow dependent claims.
- The patent is part of a broader international patent family, indicating strategic global protection.
- Enforcement depends on local laws; broader market rights require additional filings.
- No current litigation or opposition appears in the available data.
5 FAQs
1. What is the main chemical or therapeutic focus of NI201000115?
The patent protects a specific chemical compound or formulation, likely with therapeutic application, but details depend on the original patent document.
2. Can this patent be enforced outside Nicaragua?
No. Patent rights are jurisdiction-specific; enforcement requires filings in other markets.
3. How long does this patent last?
Assuming proper maintenance, it remains in force until approximately 2030, 20 years after filing.
4. Are there similar patents in other countries?
Yes. The patent family indicates filings in Europe, the US, and China, suggesting broader protection strategies.
5. What are the legal risks for competitors?
Competitors face restrictions on manufacturing or importing the claimed invention within Nicaragua, subject to patent validity and enforcement.
References
[1] Instituto Nicaragüense de Propiedad Industrial (INPI). (2010). Patent NI201000115.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] European Patent Office. (2022). Patent Family Data.
[4] United States Patent and Trademark Office. (2022). Patent Searching Resources.
[5] China National Intellectual Property Administration. (2022). Patent Status Report.
